Figo stage IIIC endometrial cancer patients undergoing surgery and adjuvant radiation therapy

2000 ◽  
Vol 48 (3) ◽  
pp. 123 ◽  
Author(s):  
K Murphy ◽  
P.P Connell ◽  
R.B McBride ◽  
A.J Mundt
Keyword(s):  
Radiation Therapy ◽  
Endometrial Cancer ◽  
Cancer Patients ◽  
Figo Stage ◽  
Adjuvant Radiation ◽  
Stage Iiic ◽  
Adjuvant Radiation Therapy

Adjuvant radiation therapy in young breast cancer patients: current state of the art and evidence-based algorithm

The Breast ◽  
2018 ◽  
Vol 41 ◽  
pp. S15
Author(s):  
Icro Meattini ◽  
Matteo Lambertini ◽  
Isacco Desideri ◽  
Alex De Caluwé ◽  
Orit Kaidar-Person ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
State Of The Art ◽  
Adjuvant Radiation ◽  
Evidence Based ◽  
Breast Cancer Patients ◽  
Adjuvant Radiation Therapy ◽  
Current State ◽  
Young Breast Cancer

scholarly journals A proposal for a new classification of “unfavorable risk criteria” in patients with stage I endometrial cancer

2019 ◽  
Vol 29 (7) ◽  
pp. 1086-1093 ◽  
Author(s):  
Richard Li ◽  
Ashwin Shinde ◽  
Ernest Han ◽  
Stephen Lee ◽  
Sushil Beriwal ◽  
...  
Keyword(s):  
Risk Factors ◽  
Radiation Therapy ◽  
Endometrial Cancer ◽  
Lymphovascular Invasion ◽  
Figo Stage ◽  
Stage I ◽  
Adjuvant Radiation ◽  
New Classification ◽  
Stage Ib

BackgroundRandomized trials describe differing sets of high–intermediate risk criteria.ObjectiveTo use the National Cancer Database to compare the impact of radiation therapy in patients with stage I endometrial cancer meeting different criteria, and define a classification of “unfavorable risk.”MethodsPatients with stage I endometrial cancer between January 2010 and December 2014 were identified in the National Cancer Database and stratified into two cohorts: (1) patients meeting Gynecologic Oncology Group (GOG)-99 criteria only for high–intermediate risk, but not Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-1 criteria and (2) those meeting PORTEC-1 criteria only. High-risk stage I patients with both FIGO stage IB (under FIGO 2009 staging) and grade 3 disease were excluded. In each cohort, propensity score-matched survival analyses were performed. Based on these analyses, we propose a new classification of unfavorable risk. We then analyzed the association of adjuvant radiation with survival, stratified by this classification.ResultsWe identified 117,272 patients with stage I endometrial cancer. Of these, 11,207 patients met GOG-99 criteria only and 5,920 patients met PORTEC-1 criteria only. After propensity score matching, adjuvant radiation therapy improved survival (HR=0.73; 95% CI 0.60 to 0.89; p=0.002) in the GOG-99 only cohort. However, there was no benefit of adjuvant radiation (HR=0.89; 95% CI 0.69 to 1.14; p=0.355) in the PORTEC-1 only cohort. We, therefore, defined unfavorable risk stage I endometrial cancer as two or more of the following risk factors: lymphovascular invasion, age ≥70, grade 2–3 disease, and FIGO stage IB. Adjuvant radiation improved survival in stage I patients with adverse risk factors (HR=0.74; 95% CI 0.68 to 0.80; p<0.001), but not in other stage I patients (HR=1.02; 95% CI 0.91 to 1.15; p=0.710; p interaction <0.001).ConclusionOur study showed that adjuvant radiation was associated with an overall survival benefit in patients meeting GOG-99 criteria only; however, no survival benefit was seen in patients meeting PORTEC-1 criteria only. We propose a definition of unfavorable risk stage I endometrial cancer: ≥2 risk factors from among lymphovascular invasion, age ≥70, grade 2–3 disease, and FIGO stage IB disease.

Survival Analysis of FIGO Stage IIIC Endometrial Cancer Patients

2010 ◽  
Vol 78 (3) ◽  
pp. S145 ◽  
Author(s):  
A.P. Brown ◽  
D.K. Gaffney ◽  
M.K. Dodson ◽  
A.P. Soisson ◽  
W.T. Sause
Keyword(s):  
Endometrial Cancer ◽  
Survival Analysis ◽  
Cancer Patients ◽  
Figo Stage ◽  
Stage Iiic

Association of fatigue and insomnia with inflammatory cytokine and hematopoetic stem cell levels in breast cancer patients undergoing adjuvant radiation therapy.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12048-e12048
Author(s):  
Fei-Fei Liu ◽  
Willa Wei Shi ◽  
M McCusker ◽  
Madeline Li ◽  
Jie Su ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Stem Cell ◽  
Cancer Patients ◽  
Inflammatory Cytokine ◽  
Adjuvant Radiation ◽  
Breast Cancer Patients ◽  
Adjuvant Radiation Therapy ◽  
General Fatigue ◽  
Hematopoetic Stem Cell

e12048 Background: Fatigue and insomnia are frequent conditions experienced by breast cancer patients during adjuvant radiation therapy (RT). Our group reported that fatigue correlates with reduced CD34+ circulating hematopoetic stem cell (HSC) levels. Our current study examined the role of inflammatory cytokines in mediating fatigue and insomnia following adjuvant RT. Methods: Phlebotomies were conducted on 148 breast cancer patients undergoing adjuvant RT at five time points: prior to RT (D1), after two (D2) and five (D5) days of treatment, during the final week of RT (Df), and one month post-RT completion (M1). CD34+, CD45+, circulating blood cell (CBC), and 17 inflammatory cytokine levels were assessed. Patients also completed questionnaires at each time point, including the multidimensional fatigue inventory (MIF-21), insomnia severity index (ISI), and hospital anxiety and depression scale (HADS). Results: CD34+, CD45+ and CBC levels decreased during treatment with adjuvant RT, with the lowest levels observed at Df (p<0.001). General fatigue significantly worsened throughout treatment from D1 to Df, returning to baseline at M1, (p<0.001; adjusted for insomnia, depression and anxiety). General fatigue worsened as CD34+ counts, hemoglobin and CBCs increased (p<0.001). Insomnia increased with reduced CD34+, CD45+ and CBCs (p<0.05). TGF-β1, MCP-1, MMP-2, IL-1ra and IFN-α2a cytokine expression varied throughout RT (p<0.01), most significantly at Df. Elevated MCP-1, TNF-RII and TNF-a levels correlated with worsening general fatigue, increased insomnia, and reduced activity and motivation (p<0.001). MMP-2 increased as IL-1ra, CD34+, CD45+ and CBC counts decreased (p<0.001). Further, the 52 patients who received prior adjuvant chemotherapy had elevated levels of fatigue, insomnia and anxiety, which correlated with high HSCs levels. Conclusions: Our findings demonstrate that fatigue and insomnia are associated with reduced HSCs and increased MCP-1, TNF-RII and TNF-a pro-inflammatory cytokines. This examination of the effect of RT on fatigue and insomnia is one of the most comprehensive longitudinal clinical evaluations of its kind.

Sign in / Sign up

Export Citation Format

Share Document